Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica

Clin Exp Rheumatol. 2010 Sep-Oct;28(5):756-8. Epub 2010 Oct 22.

Abstract

Objectives: To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice.

Methods: Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA.

Results: No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse.

Conclusions: PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giant-cell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers / blood
  • C-Reactive Protein / analysis*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Glucocorticoids / therapeutic use*
  • Humans
  • Male
  • Middle Aged
  • Polymyalgia Rheumatica / blood*
  • Polymyalgia Rheumatica / diagnosis*
  • Polymyalgia Rheumatica / drug therapy
  • Prognosis
  • Prospective Studies
  • Recurrence
  • Serum Amyloid P-Component / analysis*

Substances

  • Biomarkers
  • Glucocorticoids
  • Serum Amyloid P-Component
  • PTX3 protein
  • C-Reactive Protein